Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 4/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 4/20 | 1.00 |
| ▸ | CBS | P35520 | 2/20 | 0.73 |
| ▸ | KLK1 | P06870 | 1/20 | 0.57 |
| ▸ | KLK3 | P07288 | 1/20 | 0.57 |
| ▸ | KLK2 | P20151 | 1/20 | 0.57 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 3/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morelloflavone SCHEMBL2383075 | 1.00 | PRSS1 (1.00) | PRSS1PRSS2PRSS3CBSKLK1 | |
| SCHEMBL27165462 | 0.94 | PRSS1 (0.90) | PRSS1PRSS2PRSS3CBSKLK1 | |
| Volkensiflavone SCHEMBL13829450 | 0.94 | PRSS1 (0.89) | PRSS1PRSS2PRSS3CBSKLK1 | |
| Volkensiflavone SCHEMBL27160551 | 0.94 | PRSS1 (0.89) | PRSS1PRSS2PRSS3CBSKLK1 | |
| Volkensiflavone SCHEMBL7620161 | 0.94 | PRSS1 (0.89) | PRSS1PRSS2PRSS3CBSKLK1 | |
| Pancibiflavonol SCHEMBL13829454 | 0.86 | PRSS1 (0.76) | PRSS1PRSS2PRSS3CBSKLK1 | |
| SCHEMBL30209479 | 0.77 | PRSS1 (0.62) | PRSS1PRSS2PRSS3CBSKDM4E | |
| SCHEMBL16263265 | 0.74 | KLK1 (0.72) | PRSS1PRSS2PRSS3CBSKLK1 | |
| SCHEMBL6360284 | 0.74 | KLK1 (0.72) | PRSS1PRSS2PRSS3CBSKLK1 | |
| SCHEMBL29414343 | 0.74 | KLK1 (0.72) | PRSS1PRSS2PRSS3CBSKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109010409-A | The extraction and purification process and detection method of content of flavonoid compound in a kind of people face fruit leaf | 中南民族大学 | 2018-12-18 | — | — | CN | claimed |
| CN-106822513-A | It is a kind of to treat pharmaceutical composition of osteoproliferation and preparation method thereof | 济南昊雨青田医药技术有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-106620064-A | Medicinal composition for treating undifferentiated arthritis and preparation method of medicinal composition | 济南昊雨青田医药技术有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-106138563-A | A kind of pharmaceutical composition treating bladder cancer | 济南星懿医药技术有限公司 | 2016-11-23 | — | — | CN | claimed |
| CN-105726978-A | Summer-heat removing liquid for strengthening infants and preparation method thereof | 杭州华威药业股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| CN-105596415-A | Pharmaceutical composition for treating angina pectoris in coronary heart disease and preparation method thereof | JINAN XINGYI MED TECH CO LTD | 2016-05-25 | — | — | CN | claimed |
| CN-105497114-A | Pharmaceutical composition for treating dyspepsia and preparation method thereof | JINAN XINGYI MED TECH CO LTD | 2016-04-20 | — | — | CN | claimed |
| CN-105288202-A | Pharmaceutical composition for curing infantile cough | JINAN XINGYI MED TECH CO LTD | 2016-02-03 | — | — | CN | claimed |
| CN-105287739-A | Medicine composition for treating leucoderma and preparation method thereof | JINAN XINGYI MED TECH CO LTD | 2016-02-03 | — | — | CN | claimed |
| CN-105267289-A | Pharmaceutical composition for treating functional dyspepsia and preparation method of pharmaceutical composition | JINAN XINGYI MED TECH CO LTD | 2016-01-27 | — | — | CN | claimed |
| US-20120039796-A1 | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients | MARKOU DEMETRIOS (US) | 2012-02-16 | — | — | US | claimed |
| US-20110217293-A1 | Uses of morelloflavone | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2011-09-08 | — | — | US | claimed |
| WO-2010014199-A2 | USES OF MORELLOFLAVONE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-02-04 | — | — | WO | claimed |
| WO-2009023803-A2 | MODULATED RELEASE FORMULATION FOR THE DELIVERY OF ONE OR MORE MEDICAMENTS | ABBOTT RESPIRATORY LLC (US) | 2009-02-19 | — | — | WO | claimed |
| CN-101049301-A | Pharmaceutical preparation of biflavone compound for anti gout | HUIBEI COLLEGE OF CHINESE MEDI (CN) | 2007-10-10 | — | — | CN | claimed |
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | ADVANCED LIFE SCIENCES, INC. | 2002-06-06 | — | — | US | claimed |
| US-6399654-B1 | ADMINISTERING MIXTURE OF VIRICIDE AND BIOFLAVANOID | ADVANCED LIFE SCIENCES, INC. | 2002-06-04 | — | — | US | claimed |
| WO-1998046238-A1 | BIFLAVINOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS, ALONE OR IN COMBINATION WITH AT LEAST ONE KNOWN ANTIVIRAL AGENT | MEDICHEM RESEARCH, INC. (US) | 1998-10-22 | — | — | WO | claimed |
| EP-0833631-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1998-04-08 | — | — | EP | claimed |
| WO-1997000679-A1 | BIFLAVANOIDS AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS | MEDICHEM RESEARCH, INC. (US) | 1997-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068757-A1 | Biflavanoids and derivatives thereof as antiviral agents | HK2, GYS2, HK1 | PRSS1 2331/4885PRSS2 1604/4885PRSS3 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.